AB-601: SHMTi’s: Small Molecule Therapeutic for Rheumatoid Arthritis

This year, we worked with Dr. Joshua Rabinowitz on his innovative therapeutic candidate, SHIN2. SHIN2 is proposed primarily for Rheumatoid Arthritis (RA) and T-cell acute lymphoblastic leukemia (T-ALL), with demonstrated efficacy both in vitro and in vivo. The pathway vulnerability that this drug targets is conserved across a number of oncological and autoimmune indications, so we explored this landscape and see how best to market SHIN2 to investors in Boston, MA, pitching to companies like MPM Capital, 5AM Ventures, Pillar VC, BioLabs, and AstraZeneca.